Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30808537 | 0.90 | MAPT (0.41) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL22394632 | 0.90 | MAPT (0.41) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8481716 | 0.89 | LMNA (0.43) | EGFRMAPTCA1CA2CA12 | |
| SCHEMBL18044477 | 0.84 | SMN1; SMN2 (0.50) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18151909 | 0.81 | CA1 (0.44) | MAPTCA1CA2CA12CA9 | |
| SCHEMBL8478789 | 0.80 | EGFR (0.42) | EGFRCYP3A4CA1CA2CA12 | |
| SCHEMBL28465766 | 0.79 | TSHR (0.43) | SMN1; SMN2CYP3A4CA1CA2CA12 | |
| SCHEMBL4630496 | 0.79 | EGFR (0.45) | EGFRMAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL22394682 | 0.74 | DPP4 (0.39) | MAPTSMN1; SMN2CA1CA2CA12 | |
| SCHEMBL8479737 | 0.73 | RARA (0.39) | EGFRMAPTKMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10098975-B2 | Labeled pkg-1-alpha-binding compounds and their use in imaging and quantifying pain | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-10-16 | — | — | US | disclosed |
| EP-3013339-B1 | LABELED PKG-1-ALPHA-BINDING COMPOUNDS AND THEIR USE IN IMAGING AND QUANTIFYING PAIN | UNIV COLUMBIA (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20160243266-A1 | Labeled pkg-1-alpha-binding compounds and their use in imaging and quantifying pain | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-08-25 | — | — | US | disclosed |
| US-9402826-B2 | Neuronal pain pathway modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150126576-A1 | NEURONAL PAIN PATHWAY MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-05-07 | — | — | US | disclosed |
| US-8846742-B2 | Neuronal pain pathway modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-30 | — | — | US | disclosed |
| US-20080176920-A1 | protein kinase G inhibitors; analogs of balanol | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2008-07-24 | — | — | US | disclosed |
| EP-1919875-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | Astex Therapeutics Limited (GB) | 2008-05-14 | — | — | EP | disclosed |
| WO-2006136829-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126576-A1 | NEURONAL PAIN PATHWAY MODULATORS | GRIN3A, GRIN3B, OPRK1 | EGFR 4551/4885MAPT 970/4885SMN1; SMN2 1584/4885 |
| US-10098975-B2 | Labeled pkg-1-alpha-binding compounds and their use in imaging and quantifying pain | OPRK1, PKN1, PRKG1 | EGFR 2609/4885MAPT 1681/4885SMN1; SMN2 2007/4885 |
| US-20160243266-A1 | Labeled pkg-1-alpha-binding compounds and their use in imaging and quantifying pain | OPRK1, PKN1, PRKG1 | EGFR 2609/4885MAPT 1681/4885SMN1; SMN2 2007/4885 |
| US-20080176920-A1 | protein kinase G inhibitors; analogs of balanol | PRKCG, GRK3, PRKG1 | EGFR 1374/4885MAPT 1736/4885SMN1; SMN2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.